Nrx Pharmaceuticals Stock Price To Book
| NRXP Stock | USD 2.27 0.02 0.87% |
NRX Pharmaceuticals fundamentals help investors to digest information that contributes to NRX Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of NRX Stock. The fundamental analysis module provides a way to measure NRX Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NRX Pharmaceuticals stock.
NRX |
NRX Pharmaceuticals Company Price To Book Analysis
NRX Pharmaceuticals' Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current NRX Pharmaceuticals Price To Book | 2.90 X |
Most of NRX Pharmaceuticals' fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NRX Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, NRX Pharmaceuticals has a Price To Book of 2.9042 times. This is 88.69% lower than that of the Biotechnology sector and 51.92% lower than that of the Health Care industry. The price to book for all United States stocks is 69.46% higher than that of the company.
NRX Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NRX Pharmaceuticals' direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NRX Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NRX Pharmaceuticals by comparing valuation metrics of similar companies.NRX Pharmaceuticals is currently under evaluation in price to book category among its peers.
NRX Fundamentals
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.46 | ||||
| Current Valuation | 43.76 M | ||||
| Shares Outstanding | 16.92 M | ||||
| Shares Owned By Insiders | 16.37 % | ||||
| Shares Owned By Institutions | 5.94 % | ||||
| Number Of Shares Shorted | 1.15 M | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.66) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 1.79 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Target Price | 31.67 | ||||
| Number Of Employees | 14 | ||||
| Beta | 1.12 | ||||
| Market Capitalization | 38.74 M | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
| Working Capital | (12.16 M) | ||||
| Net Asset | 7.32 M |
About NRX Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.